Biora Therapeutics, Inc. (4ZU)

Biora Therapeutics, Inc. operates as a biotechnology company, primarily focused on developing innovative oral biotherapeutics. The company's core efforts include: 1. Targeted Therapeutics Program: This initiative employs an advanced, ingestible smart capsule engineered for the precise administration of medications directly within the gastrointestinal (GI) tract. The aim is to enhance the efficacy of treatments for inflammatory bowel diseases. 2. Systemic Therapeutics Program: Utilizing an orally delivered capsule, this program offers a non-invasive method for delivering biotherapeutics. These are released straight into the intestinal mucosa, facilitating improved absorption into the bloodstream and broader systemic effects, thereby eliminating the need for injections. Additionally, Biora Therapeutics is engaged in creating diagnostic devices. These tools are designed to evaluate the characteristics of the GI tract and identify various digestive conditions, such as small intestine bacterial overgrowth (SIBO), by enabling diagnosis directly where the disease manifests. Established in 2010, the company previously operated under the name Progenity, Inc. It rebranded as Biora Therapeutics, Inc. in April 2022 to underscore its strategic focus on its therapeutic product pipeline. Its headquarters are situated in San Diego, California.